Pharmaceutical Technologist - January 2008 - (Page 12)

*Market watch A view from the US Sandy Lutz of PricewaterhouseCoopers Health Research Institute examines the health reform proposals of the US presidential candidates — which are set to take strikingly different paths. Sandy Lutz ealthcare is the number one Domestic policy issue on the minds of American voters. Key health industry stakeholders say the current health system framework cannot be sustained and that the status quo is unacceptable. Employers believe healthcare costs are damaging corporate competitiveness in the global economy, and industry and consumer organizations are calling for systemic changes in the way in which healthcare is paid for and delivered. However, strikingly different solutions are being proposed, and the 2008 presidential election is poised to see the most significant push for major health reform in the US since 1992. The stakes for the health industry are high. The role of government in healthcare is likely to change, and could even increase through additional mandates and regulation depending on which candidate is elected. The major health-related issues of the 2008 presidential election season are: ● Covering the rising uninsured population. ● Modifying tax rules to support health system changes. ● Controlling health costs and improving quality of care. The leading Republican and Democratic presidential candidates are proposing two very different approaches to tackle these issues. The Democrats promise broad and immediate changes, with plans to decrease costs, improve quality and cover the uninsured. The Republicans have similar goals, but less detailed proposals that mostly rely on tax credits or H incentives for individuals to purchase insurance without federal mandates. Both parties’ plans will expand the federal government’s role in healthcare, and will affect individuals and businesses in significantly different ways. For example, with more of their reimbursement coming from government, providers are concerned about covering their costs, or are shifting costs to commercial plans to cover shortfalls. Covering the uninsured through public programmes is expected to cost the federal government $100 billion (€67.9 billion) to $150 billion (€101.9 billion) a year. If the government finances the expansion, it would tip the US health care system into one in which the government is the majority payer. Tipping past the halfway mark has broad implications for the industry, which increasingly will depend on government payment, which tends to be less than commercial payment. In addition, many Americans are working longer in life in part because of their access to health insurance through their employer. Currently, some 177 million Americans get their health insurance through their employers, making job-based coverage the most common source of health insurance in the US. Proposals from the presidential candidates are at opposite poles, ranging from mandated employer-sponsored coverage, which has significant financial implications for corporate America to a shift in coverage responsibility to individuals. In this article, based on our report Beyond the Sound Bite: Presidential Candidates Target Health Reform, we offer an independent, impartial analysis of the 12

Table of Contents for the Digital Edition of Pharmaceutical Technologist - January 2008

Pharmaceutical Technologist - January 2008
Contents
Editor's Comment
News
Morpheus
Market Watch
Lagging Japanese Drug R&D
Croatia’s Innovation
Integrating PAT with Biopharmaceutical Development and Manufacture
Q&A

Pharmaceutical Technologist - January 2008

Pharmaceutical Technologist - January 2008 - Pharmaceutical Technologist - January 2008 (Page 1)
Pharmaceutical Technologist - January 2008 - Pharmaceutical Technologist - January 2008 (Page 2)
Pharmaceutical Technologist - January 2008 - Contents (Page 3)
Pharmaceutical Technologist - January 2008 - Contents (Page 4)
Pharmaceutical Technologist - January 2008 - Editor's Comment (Page 5)
Pharmaceutical Technologist - January 2008 - News (Page 6)
Pharmaceutical Technologist - January 2008 - News (Page 7)
Pharmaceutical Technologist - January 2008 - News (Page 8)
Pharmaceutical Technologist - January 2008 - News (Page 9)
Pharmaceutical Technologist - January 2008 - Morpheus (Page 10)
Pharmaceutical Technologist - January 2008 - Morpheus (Page 11)
Pharmaceutical Technologist - January 2008 - Market Watch (Page 12)
Pharmaceutical Technologist - January 2008 - Market Watch (Page 13)
Pharmaceutical Technologist - January 2008 - Lagging Japanese Drug R&D (Page 14)
Pharmaceutical Technologist - January 2008 - Lagging Japanese Drug R&D (Page 15)
Pharmaceutical Technologist - January 2008 - Lagging Japanese Drug R&D (Page 16)
Pharmaceutical Technologist - January 2008 - Lagging Japanese Drug R&D (Page 17)
Pharmaceutical Technologist - January 2008 - Croatia’s Innovation (Page 18)
Pharmaceutical Technologist - January 2008 - Croatia’s Innovation (Page 19)
Pharmaceutical Technologist - January 2008 - Croatia’s Innovation (Page 20)
Pharmaceutical Technologist - January 2008 - Croatia’s Innovation (Page 21)
Pharmaceutical Technologist - January 2008 - Croatia’s Innovation (Page 22)
Pharmaceutical Technologist - January 2008 - Integrating PAT with Biopharmaceutical Development and Manufacture (Page 23)
Pharmaceutical Technologist - January 2008 - Integrating PAT with Biopharmaceutical Development and Manufacture (Page 24)
Pharmaceutical Technologist - January 2008 - Integrating PAT with Biopharmaceutical Development and Manufacture (Page 25)
Pharmaceutical Technologist - January 2008 - Integrating PAT with Biopharmaceutical Development and Manufacture (Page 26)
Pharmaceutical Technologist - January 2008 - Q&A (Page 27)
Pharmaceutical Technologist - January 2008 - Q&A (Page 28)
Pharmaceutical Technologist - January 2008 - Q&A (Page 29)
https://www.nxtbook.com/nxtbooks/advanstaruk/pt0908
https://www.nxtbook.com/nxtbooks/advanstaruk/pt0708
https://www.nxtbook.com/nxtbooks/advanstaruk/pt0508
https://www.nxtbook.com/nxtbooks/advanstaruk/pt0308
https://www.nxtbook.com/nxtbooks/advanstaruk/pt0108
https://www.nxtbook.com/nxtbooks/advanstaruk/pt1107
https://www.nxtbook.com/nxtbooks/advanstaruk/pt0907
https://www.nxtbook.com/nxtbooks/advanstaruk/pt0707
https://www.nxtbook.com/nxtbooks/advanstaruk/pt0507
https://www.nxtbook.com/nxtbooks/advanstaruk/pte0107
https://www.nxtbook.com/nxtbooks/advanstaruk/pte-mediakit07
https://www.nxtbook.com/nxtbooks/advanstaruk/pte1006
https://www.nxtbook.com/nxtbooks/advanstaruk/pte0706
https://www.nxtbook.com/nxtbooks/advanstaruk/pte0506
https://www.nxtbook.com/nxtbooks/advanstaruk/pte0406
https://www.nxtbook.com/nxtbooks/advanstaruk/pte0306
https://www.nxtbookmedia.com